It is no longer just for celebrities. The ‘Miracle’ Weight Loss Competition arrived in India last week Lillyn Mounjaro, American drug manufacturer. Price for 17,500 months after 5 mg dose of the drug has an early front. But that’s just the beginning. In the coming year, India will see the launch of competitors, including generic products for 90-95 than this.

The weight is expected to change dramatically by introducing these block drugs. “Due to clinically severe obesity, surgery was the only option (clinically obese),” Dr. Muffazal Lakdawala, a bariatric surgeon and an obesity management expert, said Mintu. “We dealt with less than 0.1 people who were qualified. 99.9 people were still not treated for their obesity, and we did not recognize obesity as a disease.”

As a chemically known tirzopatide, it is one of the drugs called GLP-1 (Glucagon-like peptide-1) that mimic GLP-1 hormone to promote the feeling of supplementation and regulate blood glucose. The GLP-1 drugs originally developed in the treatment of type 2 diabetes showed a significant opportunity to deal with weight and especially accept obesity.

Over the past few years, they have included the storm of the world, and demand is still exceeding supply. In India, the market has already been lost, but the picking has been delayed because they are not as effective. Industrial experts believe that injections such as Mounjaro and Ozempic are widely introduced.

Mounjaro leads an average of 21.8 kg of weight loss at the highest dose (15 mg) and 15.4 kg weight loss at the lowest dose (5 mg) for 72 weeks.Although Lillyn Mounjaro is the first of its kind, it’s not the only one. Danish drug manufacturer Novo Nordisk’s injection Semaglutide – sold under the brand Ozempic and Wegovy – can also launch in India sometime this year.

The innovator has not yet clarified the timeline, but he will be competing in India when the medicine goes outside the patent early next year. At the same time, India’s largest drug manufacturer Sun Pharmaceutical Industries Ltd works on its own GLP-1 medicine.

The GLP-1 market is expected to grow to $ 100 billion by 2030. There are already a few oral weight losses in India, such as orlistat and GLP-1, such as Liraglutide and Semaglutide, in the market. Novo Nordisk launched the oral Semaglutide Tablet Rybelsus in 2022.

Sources

https://www.livemint.com/industry/weight-loss-drugs-india-mounjaro-price-india-best-weight-loss-injections-glp-1-drugs-india-ozempic-vs-mounjaro-eli-lily-11742729849599.html

https://www.livemint.com/companies/news/eli-lilly-weight-loss-drug-mounjaro-comes-to-india-eyes-pharma-big-market-with-increasing-obesity-and-diabetes-risk-news-11742459356376.html